CliffBio
biologic

Octagam

Immune Globulin Intravenous (Human)

Loss of exclusivityJuly 2026projected — 12-year biologic exclusivity estimate
CompanyOctapharma Pharmazeutika Produktionsges.m.b.H.

Drug detail

Brand nameOctagam
Active ingredientImmune Globulin Intravenous (Human)
Strength10% 10G
Dosage formInjection
RouteIntravenous
ModalityBiologic
FDA approvalJuly 2014
Marketing statusRx

More from Octapharma Pharmazeutika Produktionsges.m.b.H.

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Octagam patent cliff — loss of exclusivity July 2026 | CliffBio